Overview

External Advisory Committee

Indiana University Cancer Center

September 25, 2006

Overview

Overview

• Continued strong institutional commitment

• Effective and on-going strategic planning

• Highly effective and energetic senior and program leadership team

• Seminal cancer research findings

Points of Emphasis

Strategic planning, leading to:– Key leadership changes– Enhanced prevention and control

research activity– Targeted recruitment– New and unique collaborations, including

with the Purdue Cancer Center– ITRAC is open for business– Improved translational research– New cores

To be a leading, national comprehensive cancer center based on our scientific investigation, health care delivery, and education.

Vision

Mission

IUCC seeks to reduce the burden of cancer through innovation and dissemination

Goals

1. Foster excellence in interdisciplinary translational research through established and developing research programs.

2. Provide the highest quality patient care through interdisciplinary clinical programs.

3. Develop nationally recognized interdisciplinary graduate and post-graduate education and training programs.

4. Facilitate the development and implementation of a statewide cancer control program.

Indiana UniversityBoard of TrusteesIndiana UniversityBoard of Trustees

President:Adam Herbert

President:Adam Herbert

Vice President and Chancellor:

Charles Bantz

Vice President and Chancellor:

Charles Bantz

Dean-IU SOM and VP Life Sciences IU:D. Craig Brater

Dean-IU SOM and VP Life Sciences IU:D. Craig Brater

IU Cancer Center DirectorStephen D. Williams

IU Cancer Center DirectorStephen D. Williams

$0

$10,000,000

$20,000,000

$30,000,000

$40,000,000

$50,000,000

$60,000,000

$70,000,000

NCI Other NIH ACS NSF Other PeerReview

Total

IUCC Peer Reviewed Funding

January 2004

September 2006

Senior Leaders

• Director: Williams• Deputy Director: Loehrer• AD Basic Research: Kelley• AD Clinical Research: Sweeney• AD Strategic Planning: Klaunig• AD Administration: Darling• AD Cancer Programs: Hammoudeh

AD Strategic Planning and Partnerships

• Responsible for coordination of strategic planning activities

• Interacts with other AD’s• External relations

– Purdue University– IU Bloomington including cancer

biology – IUPUI– ISDH,CDC

Purdue Cancer Center

• Monthly meetings (IUPU-L)• Two combined retreats, followed by

two rounds of pilot projects, of which at least one project led to NCI funding

• Policies for shared facility use and indirect costs

• Submission of two complex funding applications, one of which will be funded– Clinical Proteomics– Interdisciplinary Research Centers

(Cancer Care Engineering

Programs

EstablishedBreast Cancer

EDT

Hematopoiesis / Microenvironment and Immunology

Prevention and Control

DevelopingMolecular Carcinogenesis

Tumor Microenvironment

Biological MicroscopyBiostatistics*Clinical Research Office*Flow Cytometry*Tissue bank*

Transgenic and Knockout Mouse*

Transplant and Xenograft Mouse

Vector ProductionCancer

Pharmacology/Analytic*

New Cores: Angiogenesis / Endothelial Cell Translational Genomics* Chemical Genomics

* Administered by IUCC

Shared Facilities

Essential Characteristics

Facilities

•R3: 125,000 sq ft of new research space that will be assigned by IUCC; completion 1/09

“IU Cancer Center”- cancer hospital and ambulatory care facility; completion 8/08

Indiana University Cancer Center

Sam OdleClarian COO

Stephen D. Williams MD

Director, IUCC

Patrick J. Loehrer, Sr. MDDeputy Director, IUCCMedical Director, IUCC

FuadHammoudehAdministrator,

Clarian Cancer Programs

Organizational Capabilities

Organizational Capabilities: Strategic Planning

Weekly senior leaders meetingsFour planning retreats (two,SL’s only;

one with program leaders; one cancer hospital)

Updating of existing written strategic plan

Focused on:-Targeted recruitment and retention-Increasing cancer research funding-Translational clinical research-Core facility development / improvement

Organizational Capabilities: Recruitment

• Sherif Farag, MBBS, PhD (Medicine, H/O)– Director of BMT and malignant hematology– Recent R21 and current NIH funding– Translational cancer research in HMI

• Yan Xu, PhD (Ob Gyn)– Two NCI grants– EDT member focusing on ovarian cancer

• Angelo Cardoso, MD, PhD (Medicine, H/O) – HMI member– Marrow microenvironment / leukemia and

metastasis

• Nadia Carlesso, MD, PhD(Pediatrics, Wells)– HMI member; NIH funding– Notch signaling in leukemia

• Hua Lu, PhD (Biochemistry)– Three NCI grants– Will hold IUCC endowed chair– Basic research with GI focus

Organizational Capabilities:Recruitment

Recruitment (cont)

•Lindsey Mayo, PhD (Pediatrics, Wells)–Basic cancer research–NCI R01 funded

•Prevention and control x 3•Biochemistry x 4

Interdisciplinary and Trans-disciplinary Coordination and Collaboration

Interdisciplinary Collaboration

• All programs meet or exceed guideline requirements for collaborative publications

• Multiple examples will be presented– Pharmacogenetics of tamoxifen and

AI’s– JNK Inhibition in AML– Parthenolide Analogues

Interdisciplinary Collaboration: Prevention and Control

• Narrowed and refined focus• Health services research (several

participants)• Adolescent medicine• Psychology, psychiatry, and clinical

epidemiology• Meetings and retreat• Increased funding and co-publications• Funding of NCI R25 training grant:

“Training in Research for Behavioral Oncology and Cancer Control?”

• Noteworthy scientific collaborations and accomplishments

• David Haggstrom, MD– General internist co-recruited with RI HSR– GIM and NCI prevention fellowship– Focuses on GI cancer screening and QOL

• Karen Hudmon, DrPh– NCI funded researcher – Focuses of tobacco control– Co-recruited with RI / HSR and Purdue

• Andrew Saykin, PsyD– NCI funded senior investigator– Director of IUSM Neuroimaging– “Chemobrain” in breast cancer patients



• With Regenstrief health services resarch group: mid-senior level cancer HSR researcher

• With Peds adolescent medicine: cancer researcher who focuses on risky behaviors, preferably smoking

• With Center of Environmental Health and Genetics, epidemiology group

Cancer Focus

Cancer Focus

• Increase cancer research funding– Recruitment– Pilot projects– Budget supplements

• ITRAC• Protocol specific research and R21

working group• HMI program

– Translational research meetings– Recruitment of Dr. Farag

Institutional Commitment


• Top priority: cancer research• New buildings and role of the IU

Cancer Center– R3: 125+k sq ft ($85 m)– Cancer hospital: “IU Cancer Center”

($150 m)

• Annual support of about $1.25 m• Additional $4.4m for recruitment

Institutional Commitment: Development

• IUCC development staff increased from two to three FTE’s

• Development for both hospital and SOM managed by this staff; report to IUCC director

6/03 9/06Endowment $4.1m $12.7m*Non-endowed $1.1m $3.4m

*includes 7 chairs and professorships

Institutional Commitment: 3D

• SOM initiative to more equitably allocate resources and indirect costs

• Departments will receive a significant proportion of indirect costs, but will be responsible for rent

• Rent for space of investigators occupying IUCC space will be passed through to departments as will indirects

• Bottom line: IUCC will continue to receive annual support and with departments will allocate space efficiently to most productive investigators


• Center of Environmental Health– Director: Jim Klaunig– “Genes, the environment and cancer”

• IUB cancer biology program– Medical sciences program– Director and up to eight faculty slots– IUCC members and senior leaders lead

search– Mission is to add to the research

capability of the IU Cancer Center

Center Director

Director

• Reports to Dean; status similar to chairs

• Assigns space; allocates budget• Membership decisions• Appoints senior and program

leaders• Leads development• Represents Indiana University

Examples

• Chair: Radiation Oncology Search• School-wide leadership in bio-

specimen management and ITRAC• IUB cancer biology program and

search• Identifying and initiating critical core

facilities– Clinical pharmacology and analytic core– Translational genomics– Angiogenesis and endothelial cell

Summary

• Diligent strategic planning in the setting of a supportive institution, leading to:– Highly interactive programs– Novel local and state-wide collaborations– Key recruitments– Sophisticated new shared facilities– Important discoveries for the prevention,

detection, and treatment of cancer

Future Directions

• Biospecimen management– Informatics– Pathology

• ITRAC• Translational research• Unique state-wide collaborations

– Purdue– HOG– Indiana Cancer Consortium

Future Directions

• Continued targeted recruitment– Prevention and control– Breast cancer metastasis /

genomics– Epidemiology– Radiation oncology– Clinical investigators

Overview

Health & Medicine

Transcript of Overview